Advertisement

Biotech start-up EggLogics develops game-changing technologies to boost in-vitro fertilisation’s success rate

●    The proprietary technologies developed by EggLogics Limited in Hong Kong are set to optimise the in-vitro fertilisation (IVF) process significantly.
●    A winner of Hong Kong Trade Development Council (HKTDC)’s 2022 Start-up Express entrepreneurship development programme and a recipient of AMTD SpiderNet Start-up Award Winner, EggLogics is on track to explore global market opportunities.  

Paid Post:Hong Kong Trade Development Council
Reading Time:5 minutes
Why you can trust SCMP
Biotech start-up EggLogics develops game-changing technologies to boost  in-vitro fertilisation’s success rate

[The content of this article has been produced by our advertising partner.]

Although IVF has been available for over 40 years, there was not any breakthrough in egg technology aimed at improving its success rate considerably, until EggLogics’ potentially game-changing proprietary technologies developed to ‘recharge’ eggs from women, particularly those over 35 years.

It’s a matter of racing against the clock for women above 35 years of age who undergo IVF to have their first live births, because of the progressively declining quality of their eggs. The success rate for women around 40 is 10 percent, meaning they have to undergo 10 rounds of IVF to have a successful live birth. The extracted ‘unusable’ eggs are discarded. Not only is the treatment costly, it is also emotionally distressing for the couples seeking help. 

“My goal is to improve the success rate of IVF by creating more ‘usable’ eggs,” says Dr Lee Tin-lap, Founder and Chairman of EggLogics. “Promoting egg’s health is a logical solution. Hence our name, EggLogics.” Dr Lee is a former Professor at the School of Biomedical Sciences, the Chinese University of Hong Kong (CUHK). 

A winner of the 2022 Start-up Express programme, organised by the HKTDC, EggLogics has developed a series of “EggCellent technology” which combines cutting-edge research in clinical science, regenerative biomedicine, genomics, biomedical engineering and bioinformatics. Three proprietary technologies, that are non-invasive and entirely ethical, have been in preliminary clinical trials. “EggBoost” is an egg-enrichment technology to improve the quality and quantity of ‘usable’ eggs and promote egg maturation. This chip, together with the proprietary cell and culture medium promote egg energy function for their healthier development and better reproductive outcomes. This technique is also applicable for egg freezing.

Advertisement